The recent Cochrane review has cast doubt on the effectiveness of amyloid-targeting drugs for Alzheimer’s disease, suggesting they do not provide significant clinical benefits despite their high costs and potential side effects. The analysis, based on data from 17 clinical trials with over 20,000 participants, indicates these drugs offer only trivial effects and pose risks such as brain swelling and microhemorrhages. Lead researcher Francesco Nonino from the IRCCS Institute of Neurological Sciences in Bologna emphasized the need for Alzheimer’s research to explore alternative treatment pathways beyond the amyloid hypothesis.
In response to these findings, the Czech-based H2 Global Group has proposed a different approach to Alzheimer’s treatment, focusing on the use of molecular hydrogen. This proposal was presented to all 27 EU member states, highlighting the potential of a combined therapy using molecular hydrogen and VR cognitive rehabilitation. The VR component, developed by a partner company, is already in use as a certified medical device in over 40 European hospitals. The company’s strategy is supported by its patent “Prophylactic or Therapeutic Agent for Dementia,” which protects the use of gaseous hydrogen in treating Alzheimer’s-type dementia and early cognitive decline.
H2 Global Group’s Chief Medical Officer, PharmDr. Milan Krajíček, pointed out that targeting only beta-amyloid is insufficient for tackling Alzheimer’s. The company’s approach aims to reduce oxidative stress and neuroinflammation, key factors in neurodegeneration. This method builds on foundational research by Professor Shigeo Ohta of Nippon Medical School, whose 2007 study in Nature Medicine demonstrated the antioxidant effects of hydrogen. Further studies have confirmed its neuroprotective properties, leading to a clinical study by H2 Global, approved by SÚKL and the Ethics Committee of University Hospital Ostrava, to register a new medical device using molecular hydrogen.
CEO and Founder of H2 Global Group, David Maršálek, emphasized the potential for a major clinical study originating from the Czech Republic, which could offer a viable and cost-effective solution to the dementia crisis affecting millions. He highlighted the strategic opportunity to combine Czech innovation with European collaboration to address the pressing challenges of an aging population and the dementia epidemic. The company’s innovative approach promises to provide a safe, accessible, and functional treatment option, urging immediate action to make this vision a reality.